Nevertheless, our proof‐of‐concept findings suggest that KDM5A inhibition could be a potential therapeutic strategy to reverse degenerative features in IBM, an inflammo‐degenerative disease where inflammation, loss of proteostasis, metabolic homeostasis and myogenic differentiation are interconnected. The gene discussed is KDM5A; the disease is inclusion body myositis.